PD-1 Inhibitor Raises PFS in Advanced Acral Melanoma

(MedPage Today) -- First-line treatment of advanced acral melanoma with the PD-1 inhibitor toripalimab (Loqtorzi) resulted in a small but statistically significant increase in progression-free survival (PFS) compared with treatment with dacarbazine...